Edition:
United Kingdom

Stryker Corp (SYK.N)

SYK.N on New York Stock Exchange

202.91USD
20 Jun 2019
Change (% chg)

$2.42 (+1.21%)
Prev Close
$200.49
Open
$202.50
Day's High
$203.81
Day's Low
$202.50
Volume
27,463
Avg. Vol
300,537
52-wk High
$203.81
52-wk Low
$144.77

Latest Key Developments (Source: Significant Developments)

Stryker Receives FDA Premarket Approval For The Neuroform Atlas Stent System To Treat Brain Aneurysms
Monday, 20 May 2019 

May 20 (Reuters) - Stryker Corp ::STRYKER RECEIVES FDA PREMARKET APPROVAL FOR THE NEUROFORM ATLAS STENT SYSTEM TO TREAT BRAIN ANEURYSMS.  Full Article

Stryker Acquires Orthospace Ltd
Thursday, 14 Mar 2019 

March 14 (Reuters) - Stryker Corp ::STRYKER ACQUIRES ORTHOSPACE, LTD..STRYKER CORP - ALL CASH TRANSACTION FOR AN UPFRONT PAYMENT OF $110 MILLION AND FUTURE MILESTONE PAYMENTS OF UP TO AN ADDITIONAL $110 MILLION..STRYKER CORP - TRANSACTION IS EXPECTED TO HAVE AN IMMATERIAL IMPACT TO NET EARNINGS IN 2019..STRYKER CORP - DEAL FOR AN UPFRONT PAYMENT OF $110 MILLION AND FUTURE MILESTONE PAYMENTS OF UP TO AN ADDITIONAL $110 MILLION.  Full Article

Stryker Corp Files For Potential Mixed Shelf Offering; Size Not Disclosed
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Stryker Corp ::STRYKER CORP FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Stryker Q4 Earnings Per Share $5.44
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Stryker Corp ::STRYKER REPORTS 2018 RESULTS AND 2019 OUTLOOK.Q4 ADJUSTED EARNINGS PER SHARE $2.18.Q4 EARNINGS PER SHARE $5.44.Q4 EARNINGS PER SHARE ESTIMATE $2.15 -- REFINITIV IBES DATA.SEES Q1 ADJUSTED EARNINGS PER SHARE $1.80 TO $1.85.Q4 SALES $3.8 BILLION VERSUS REFINITIV IBES ESTIMATE OF $3.74 BILLION.Q1 EARNINGS PER SHARE VIEW $1.84 -- REFINITIV IBES DATA.EXPECT 2019 ORGANIC NET SALES GROWTH TO BE IN RANGE OF 6.5% TO 7.5%.EXPECT ADJUSTED NET EARNINGS PER DILUTED SHARE TO BE IN RANGE OF $8.00 TO $8.20 FOR 2019.  Full Article

Stryker Announces Pricing Of €2.25 Bln Senior Notes Offering
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Stryker Corp ::STRYKER ANNOUNCES PRICING OF €2.25 BILLION SENIOR NOTES OFFERING.STRYKER CORP - PRICED NOTES EUR 550 MILLION AGGREGATE PRINCIPAL AMOUNT OF COMPANY'S 1.125% NOTES DUE 2023.STRYKER CORP - PRICED EUR 750 MILLION AGGREGATE PRINCIPAL AMOUNT OF COMPANY'S 2.125% NOTES DUE 2027.STRYKER CORP - PRICED EUR 650 MILLION AGGREGATE PRINCIPAL AMOUNT OF COMPANY'S 2.625% NOTES DUE 2030.STRYKER CORP - PRICED EUR 300 MILLION AGGREGATE PRINCIPAL AMOUNT OF COMPANY'S FLOATING RATE NOTES DUE 2020.  Full Article

Reg-Stryker Reports Q3 2018 Operating Results
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Stryker Corp ::REG-STRYKER REPORTS THIRD QUARTER 2018 OPERATING RESULTS.SEES Q4 ADJUSTED EARNINGS PER SHARE $2.13 TO $2.18.Q3 ADJUSTED EARNINGS PER SHARE $1.69.Q3 EARNINGS PER SHARE $1.55.Q3 SALES $3.2 BILLION VERSUS I/B/E/S VIEW $3.26 BILLION.Q3 EARNINGS PER SHARE VIEW $1.68 -- THOMSON REUTERS I/B/E/S.NOW EXPECT 2018 ORGANIC NET SALES GROWTH TO BE AT HIGH END OF RANGE OF 7.0% TO 7.5%.EXPECT 2018 ADJUSTED NET EARNINGS PER DILUTED SHARE TO BE IN THE RANGE OF $7.25 TO $7.30.NOW EXPECT 2018 ORGANIC NET SALES GROWTH, WHICH EXCLUDES SOME IMPACT TO BE AT HIGH END OF RANGE OF 7.0% TO 7.5%.EXPECT 2018 ADJUSTED NET EARNINGS PER DILUTED SHARE TO BE IN RANGE OF $7.25 TO $7.30.Q4 EARNINGS PER SHARE VIEW $2.13 -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $7.25, REVENUE VIEW $13.54 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

K2M Group Says plaintiff In Brown Lawsuit Has Agreed To Withdraw Motion For A Preliminary Injunction
Monday, 22 Oct 2018 

Oct 22 (Reuters) - K2M Group Holdings Inc ::K2M GROUP HOLDINGS INC - PLAINTIFF IN BROWN LAWSUIT HAS AGREED TO WITHDRAW MOTION FOR A PRELIMINARY INJUNCTION - SEC FILING.  Full Article

K2M Group - Stryker Re-Filed Pre-merger Notification With FTC And U.S. Department Of Justice
Thursday, 18 Oct 2018 

Oct 18 (Reuters) - K2M Group Holdings Inc ::K2M GROUP - ON OCT 17, STRYKER RE-FILED PREMERGER NOTIFICATION WITH FTC AND U.S. DEPARTMENT OF JUSTICE UNDER HART-SCOTT-RODINO ACT IN COMMECTION WITH DEAL WITH CO'S UNIT AND K2M.K2M GROUP HOLDINGS - NOTIFICATION INITIATED A NEW WAITING PERIOD UNDER HART-SCOTT-RODINO ACT THAT WILL EXPIRE ON NOVEMBER 16, 2018 - SEC FILING.  Full Article

Stryker Acquires Hyperbranch Medical Technology For $220 Mln
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Stryker Corp ::REG-STRYKER ACQUIRES HYPERBRANCH MEDICAL TECHNOLOGY, INC..STRYKER CORP - DEAL FOR APPROXIMATELY $220 MILLION IN AN ALL CASH TRANSACTION..STRYKER CORP - TRANSACTION IS EXPECTED TO HAVE AN IMMATERIAL IMPACT TO NET EARNINGS IN 2018..  Full Article

Stryker Announces 510(K) Clearance Of SpineJack Implantable Fracture Reduction System
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Stryker Corp ::STRYKER ANNOUNCES 510(K) CLEARANCE OF SPINEJACK® IMPLANTABLE FRACTURE REDUCTION SYSTEM.HAS RECEIVED FDA 510(K) CLEARANCE TO MARKET SPINEJACK IMPLANTABLE FRACTURE REDUCTION SYSTEM.PLANS TO EXECUTE A LIMITED LAUNCH OF SPINEJACK SYSTEM DEVICE FOR REMAINDER OF 2018.  Full Article

Photo

U.S. healthcare stocks shielded from political pressures prove profitable

NEW YORK U.S. healthcare investors have found success this year buying stocks of companies whose products improve eyesight, treat pets and fix crooked teeth, all viewed as unlikely to fall victim to political and regulatory issues pressuring a wide swath of the sector.